Position in AGMB
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$16,259,500
New position
Shares Held
1,550,000
first reported quarter
Ownership
3.15%
of shares outstanding
% of Portfolio
1.23%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Casdin Capital, LLC holds $705,487,766 across 26 Biotechnology names. AGMB ranks #10 (2.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
2,577,333 | $250,645,634 | |
| 2 | RLAY |
Relay Therapeutics, Inc.
|
14,418,574 | $143,464,811 | |
| 3 | GPCR |
Structure Therapeutics Inc.
|
1,175,000 | $56,635,000 | |
| 4 | DNLI |
Denali Therapeutics Inc.
|
1,840,000 | $35,328,000 | |
| 5 | BEAM |
Beam Therapeutics Inc.
|
1,350,000 | $32,170,500 | |
| 6 | NGNE |
Neurogene Inc.
|
1,420,361 | $28,634,477 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
75,000 | $24,815,250 | |
| 8 | MAZE |
Maze Therapeutics, Inc.
|
758,857 | $22,651,881 |
All Filings in AGMB
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $16,259,500 | 1,550,000 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||